Supira Medical, a clinical-stage Shifamed portfolio company, is focused on the development of a next-generation pVAD for use in high-risk patients undergoing interventional procedures and experiencing cardiogenic shock. To date, the Supira System has benefited 85 HRPCI patients.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
03/31/25	$120,000,000	Series E	415 AMED Ventures Cormorant Asset Management Novo Holdings PA MedTech VC Fund Qatar Investment Authority The Capital Partnership Unorthodox Ventures	undisclosed